A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07116486
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiopharmaceutical 18F-FSPG — DIAGNOSTIC_TEST
    Given by injection

Study Details

To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

Key Dates

Start date
Dec 2, 2025
Status verified
Jun 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2032

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Single Arm
    Participants will be scheduled for a baseline investigational 18F-FSPG PET/CT scan within 4 weeks of SOC CT and no more than 2 weeks prior to Y90 treatment.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Simone Krebs, MD
[email protected]
713-563-6726
Simone Krebs, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies